Dmitry Balyasny’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Dmitry Balyasny’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-15,614	Closed	-$67.5K	–	3236
2024 Q1	$67.5K	Buy	+15,614	New	+$54.4K	﹤0.01%	2512
2023 Q1	–	Sell	-13,241	Closed	-$71.9K	–	3264
2022 Q4	$71.9K	Buy	+13,241	New	+$111K	﹤0.01%	2295
2022 Q3	–	Sell	-28,394	Closed	-$140K	–	3352
2022 Q2	$140K	Sell	28,394 -781	-3%	-$4.33K	﹤0.01%	2246
2022 Q1	$222K	Buy	+29,175	New	+$277K	﹤0.01%	1996
2019 Q1	–	Sell	-15,135	Closed	-$290K	–	1715
2018 Q4	$290K	Buy	+15,135	New	+$567K	﹤0.01%	1237
2018 Q3	–	Sell	-6,554	Closed	-$285K	–	2114
2018 Q2	$285K	Buy	+6,554	New	+$281K	﹤0.01%	1538

Other funds holding GTHX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dmitry Balyasny's GTHX Position: Q2 2024 in Review

Dmitry Balyasny sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2024, closing a stake of 15,614 shares — an estimated $67.5K sold.

Dmitry Balyasny first reported a position in GTHX in Q2 2018 and held it in 6 quarters. The position peaked at $290K in Q4 2018. 88 funds tracked by Wall St. Rank hold GTHX as of Q2 2024.

Dmitry Balyasny reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Dmitry Balyasny sold 15,614 G1 Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $67.5K.
Dmitry Balyasny first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Dmitry Balyasny's G1 Therapeutics, Inc. Common Stock position peaked at $290K in Q4 2018.
88 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.